(such as #Comirnaty XFG & #Spikevax XFG) to align with dominant circulating strains.
While these early human immunogenicity data confirm a robust antibody boost, current pseudovirus assays do not directly establish long-term durability or real-world clinical effectiveness against symptomatic dx.
